Journal of Infectious Diseases and Medicine

Neuroinfections caused by herpesviruses, primarily HHV-1, pose a significant challenge for modern medicine due to the scarcity of therapeutic substances in the pharmaceutical industry. Furthermore, HHV-1 infection has been linked to neurodegenerative processes like Alzheimer's disease, justifying the search for new effective treatments. The advancement of nanotechnology opens up new avenues for treating neuroinflammation. Gold and silver nanoparticles are becoming increasingly popular, and the number of clinical trials involving metallic nanoparticles is growing all the time. The research on gold and silver nanoparticles and their potential use in the treatment of herpesvirus neuroinfection is reviewed in this paper.

The World Health Organization recently declared human monkeypox virus infection a public health emergency of international concern (PHEIC). Furthermore, there is little literature on the use of antivirals in monkeypox virus infection. This systematic review compiles all evidence on the efficacy, safety, and mechanisms of action of various antivirals. All original studies mentioning individual patient data on the use of antivirals in patients with monkeypox virus infection were reviewed. Tecovirimat is the most commonly used and has proven to be beneficial in a number of aggravating cases. Its use revealed no major safety concerns. Topical trifluridine was used as an adjuvant treatment option along with Tecovirimat. BCV and CDV were rarely used, with the latter frequently used due to the Tecovirimat is not available. Treatment discontinuation due to adverse events was linked to BCV.